Company intelligence / Profile preview

Sanitas

Kaunas, Lithuania

Ownership: Private
Employees: ~1100
Development stage: Other

Overview

Sanitas produced and marketed approximately 150-200 generic and branded generic medicines across multiple therapeutic areas in Central/Eastern Europe, with extensive manufacturing capabilities (including GMP-compliant facilities for sterile injectables, eye drops, and ointments). Not engaged in novel molecule clinical R&D.

Therapeutic areas: ImmunologyOphthalmologyGastroenterologyInfectious DiseasesNeurologyPulmonologyMen's HealthOtherDermatology
Modalities: Small moleculeBiologicInjectableTabletCapsuleEye dropOintment
Industry: Biotech

Partnerships

No major global pharma R&D partnerships reported; regional distribution and acquisition-based expansion

Beyond the preview

Go deeper on Sanitas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanitas.

Explore the full profile